MX387527B - Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas. - Google Patents

Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas.

Info

Publication number
MX387527B
MX387527B MX2019005269A MX2019005269A MX387527B MX 387527 B MX387527 B MX 387527B MX 2019005269 A MX2019005269 A MX 2019005269A MX 2019005269 A MX2019005269 A MX 2019005269A MX 387527 B MX387527 B MX 387527B
Authority
MX
Mexico
Prior art keywords
variable domains
single variable
formulations
stable
immunoglobulin
Prior art date
Application number
MX2019005269A
Other languages
English (en)
Spanish (es)
Other versions
MX2019005269A (es
Inventor
Ann Brige
Filip Callewaert
Hans Ulrichts
Brabandere Veronique De
Yves Meyvis
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of MX2019005269A publication Critical patent/MX2019005269A/es
Publication of MX387527B publication Critical patent/MX387527B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2019005269A 2013-05-17 2014-05-16 Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas. MX387527B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824523P 2013-05-17 2013-05-17
PCT/EP2014/060107 WO2014184352A1 (en) 2013-05-17 2014-05-16 Stable formulations of immunoglobulin single variable domains and uses thereof

Publications (2)

Publication Number Publication Date
MX2019005269A MX2019005269A (es) 2019-09-04
MX387527B true MX387527B (es) 2025-03-12

Family

ID=49304267

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005269A MX387527B (es) 2013-05-17 2014-05-16 Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas.
MX2015015722A MX364664B (es) 2013-05-17 2014-05-16 Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015015722A MX364664B (es) 2013-05-17 2014-05-16 Formulaciones estables de dominios variables sencillos de inmunoglobulina y usos de las mismas.

Country Status (25)

Country Link
US (2) US10035862B2 (enExample)
EP (2) EP2996720B1 (enExample)
JP (2) JP6433986B2 (enExample)
KR (1) KR102166399B1 (enExample)
CN (3) CN110063935B (enExample)
AU (3) AU2014267222B2 (enExample)
BR (1) BR112015028411B1 (enExample)
CA (1) CA2912670A1 (enExample)
CY (1) CY1122090T1 (enExample)
DK (1) DK2996720T3 (enExample)
ES (2) ES2895150T3 (enExample)
HR (1) HRP20190954T1 (enExample)
HU (1) HUE044392T2 (enExample)
LT (1) LT2996720T (enExample)
MX (2) MX387527B (enExample)
NL (1) NL1040254C2 (enExample)
PH (1) PH12015502591B1 (enExample)
PL (2) PL2996720T3 (enExample)
PT (2) PT3511018T (enExample)
RS (1) RS58857B1 (enExample)
RU (1) RU2671977C2 (enExample)
SI (1) SI2996720T1 (enExample)
SM (1) SMT201900359T1 (enExample)
TR (1) TR201908663T4 (enExample)
WO (1) WO2014184352A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
CN107406497A (zh) 2014-12-19 2017-11-28 埃博灵克斯股份有限公司 半胱氨酸连接的纳米抗体二聚体
CN111035754A (zh) * 2016-03-23 2020-04-21 兆科药业（合肥）有限公司 抗血小板溶栓素在制备治疗血栓性血小板减少性紫癜的药物中的应用
GB201612043D0 (en) 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
WO2018085551A2 (en) * 2016-11-02 2018-05-11 Polaris Group Formulations of pegylated arginine deiminase
CN111670202A (zh) 2018-02-06 2020-09-15 埃博灵克斯股份有限公司 以免疫球蛋白单可变结构域治疗ttp初次发作的方法
RS67043B1 (sr) 2018-07-03 2025-08-29 Fennec Pharmaceuticals Inc Formulacije anhidrovanog natrijum tiosulfata
JP7653352B2 (ja) * 2018-09-05 2025-03-28 エクスプレステック、リミテッド、ライアビリティ、カンパニー 免疫グロブリンａ製剤
MY205764A (en) * 2018-10-10 2024-11-12 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN110564841A (zh) * 2019-09-19 2019-12-13 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） 脑缺血相关基因作为缺血性卒中行为学特征分析的生物标记的应用
CN110624105B (zh) * 2019-09-24 2021-06-11 苏州大学 血管性血友病因子的结构敏感多肽抗原的序列
JP7502861B2 (ja) * 2019-12-27 2024-06-19 旭化成株式会社 標的物質と両親媒性高分子との複合体の形成反応の反応温度の評価方法
CN113908254B (zh) * 2021-10-19 2024-05-28 山西锦波生物医药股份有限公司 一种干粉吸入剂及其制备方法和用途
CN115850493B (zh) * 2022-11-08 2024-03-12 江苏耀海生物制药有限公司 一种二价纳米抗体Cablivi的分离纯化方法
WO2025240928A1 (en) * 2024-05-16 2025-11-20 Vega Therapeutics, Inc. Treatment of von willebrand disease

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
NZ285664A (en) 1994-05-18 1998-07-28 Inhale Therapeutic Syst Dry powder interferon composition adapted for pulmonary delivery
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
JP2000515002A (ja) 1996-06-27 2000-11-14 フラームス・インテルウニフェルジテール・インスティテュート・フォール・ビオテヒノロジー・ヴェーゼットウェー 標的分子の活性部位またはクレフトと特異的に相互作用する認識分子
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
WO1999023221A2 (en) 1997-10-27 1999-05-14 Unilever Plc Multivalent antigen-binding proteins
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
WO2000040968A1 (en) 1999-01-05 2000-07-13 Unilever Plc Binding of antibody fragments to solid supports
AU2291700A (en) 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
NZ513356A (en) 1999-02-05 2004-01-30 Univ Leiden Method of modulating metabolite biosynthesis in recombinant cells using an AP2-domain transcription factor that is involved in the response of a plant cell to a jasmonate
US6617122B1 (en) 1999-03-15 2003-09-09 Xenon Genetics, Inc. Process for identifying modulators of ABC1 activity
CN1252264C (zh) 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原－结合蛋白抑制病毒感染
ATE422545T1 (de) 1999-06-18 2009-02-15 Cv Therapeutics Inc Regulierung mittels atp binding cassette transporter proteins abc1
EP1198572A2 (en) 1999-08-02 2002-04-24 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
EP1242460B1 (en) 1999-11-29 2006-10-18 Unilever Plc Immobilisation of proteins using a polypeptide segment
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
EP1134231B1 (en) 2000-03-14 2009-04-15 Unilever N.V. Antibody heavy chain variable domains against human dietary lipases, and their uses
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
US6723359B2 (en) 2001-10-18 2004-04-20 Firmenich Sa Spray-dried compositions and method for their preparation
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
JP4323317B2 (ja) 2001-12-21 2009-09-02 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） 可変領域配列のクローニング方法
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
AU2003251238A1 (en) 2002-08-07 2004-02-25 Umc Utrecht Holding B.V. Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
BRPI0315666B8 (pt) 2002-10-23 2021-05-25 Ludwig Inst For Cancer Res Ltd dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP2284192A3 (en) 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
CA2593328C (en) 2005-01-14 2018-02-06 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
AU2006256030B2 (en) * 2005-06-10 2012-06-21 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
EP2004690A2 (en) 2006-03-13 2008-12-24 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008068280A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
MX2009010179A (es) * 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
WO2009086400A2 (en) * 2007-12-28 2009-07-09 Baxter International Inc. Recombinant vwf formulations
EP2249809A1 (en) * 2008-01-15 2010-11-17 Abbott GmbH & Co. KG Powdered protein compositions and methods of making same
CA2718081A1 (en) * 2008-03-21 2009-09-24 Ablynx Nv Von willebrand factor specific binders and methods of use therefor
CN102089325A (zh) 2008-04-17 2011-06-08 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽
DK2349314T3 (da) * 2008-10-21 2013-05-27 Baxter Int Lyofiliserede præparater af rekombinant VWF
KR101593285B1 (ko) * 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US20120321640A1 (en) 2009-12-01 2012-12-20 Ablynx N.V. Von willebrand factor specific binding agents and uses thereof
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
ES2738114T3 (es) * 2010-02-11 2020-01-20 Ablynx Nv Métodos y composiciones para la preparación de aerosoles
US20120225072A1 (en) * 2011-03-02 2012-09-06 Ablynx N.V. Stable formulations of immunoglobulin single variable domains and uses thereof
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.

Also Published As

Publication number Publication date
PH12015502591A1 (en) 2016-02-29
JP6952019B2 (ja) 2021-10-20
RU2015154214A (ru) 2017-06-22
PT3511018T (pt) 2021-10-15
PL3511018T3 (pl) 2022-01-10
RU2018137504A3 (enExample) 2021-12-28
JP2016520075A (ja) 2016-07-11
RS58857B1 (sr) 2019-07-31
CY1122090T1 (el) 2020-11-25
BR112015028411B1 (pt) 2023-01-10
CN110037983A (zh) 2019-07-23
RU2671977C2 (ru) 2018-11-08
AU2021200035A1 (en) 2021-02-25
LT2996720T (lt) 2019-07-10
EP3511018B1 (en) 2021-07-28
CN110063935B (zh) 2021-11-09
ES2731922T3 (es) 2019-11-19
EP3511018A1 (en) 2019-07-17
ES2895150T3 (es) 2022-02-17
KR20160007657A (ko) 2016-01-20
HUE044392T2 (hu) 2019-10-28
EP2996720B1 (en) 2019-03-27
AU2019201307A1 (en) 2019-03-14
HK1218258A1 (zh) 2017-02-10
US20160090424A1 (en) 2016-03-31
AU2014267222B2 (en) 2018-12-13
KR102166399B1 (ko) 2020-10-16
SMT201900359T1 (it) 2019-07-11
US20190010249A1 (en) 2019-01-10
CN110063935A (zh) 2019-07-30
JP2019034967A (ja) 2019-03-07
PT2996720T (pt) 2019-07-04
BR112015028411A2 (pt) 2017-12-12
NL1040254C2 (en) 2014-11-24
DK2996720T3 (da) 2019-06-24
TR201908663T4 (tr) 2019-07-22
AU2019201307B2 (en) 2021-01-28
AU2014267222A1 (en) 2015-11-12
US10035862B2 (en) 2018-07-31
HRP20190954T1 (hr) 2019-07-26
RU2018137504A (ru) 2018-12-14
PL2996720T3 (pl) 2019-09-30
MX364664B (es) 2019-05-03
CA2912670A1 (en) 2014-11-20
JP6433986B2 (ja) 2018-12-05
CN105339003B (zh) 2018-11-20
MX2019005269A (es) 2019-09-04
EP2996720A1 (en) 2016-03-23
CN105339003A (zh) 2016-02-17
PH12015502591B1 (en) 2016-02-29
SI2996720T1 (sl) 2019-07-31
MX2015015722A (es) 2016-03-16
WO2014184352A1 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
PH12015502591B1 (en) Stable formulations of immunoglobulin single variable domains and uses thereof
BR112019001099A2 (pt) usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc
AR109528A1 (es) Mutaciones estabilizantes de trímeros de proteínas de la envoltura del vih
EA201890456A1 (ru) Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
EA201890729A1 (ru) Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками
PL3298033T3 (pl) Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
EA201791841A1 (ru) Новые белки, специфичные к пиовердину и пиохелину
MX375448B (es) Composiciones farmacéuticas en polvo seco estables al calor y métodos.
BR112017006178A2 (pt) região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
MX2018012394A (es) Variantes de polipeptido ph20, formulaciones y usos de las mismas.
EA201990900A1 (ru) Стабильный при комнатной температуре лиофилизированный белок
BR112017014615A2 (pt) proteínas de fusão de multi-direcionamento e seus usos
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
PT3019533T (pt) Proteínas de fusão de imunoglobulinas de hélices super-enroladas e composições das mesmas
WO2015058173A8 (en) Stable solid units and methods of making the same
EA201791733A1 (ru) Производные 9h-пирролодипиридина
MX2019014397A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
CO2017000030A2 (es) Moléculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
BR112018013246A2 (pt) rótulo de peptídeo e proteína rotulada incluindo o mesmo
EA201501028A1 (ru) Конструкции митохондриальных белков и их применение
EA201691691A1 (ru) Белки слияния tatk-cdkl5, их композиции, составы и применение
SG10201903142RA (en) Serpin fusion polypeptides and methods of use thereof
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins